Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 13

Results For "LA"

7093 News Found

FDA approves EMBLAVEO for the treatment of adults with complicated intra-abdominal infections
News | February 08, 2025

FDA approves EMBLAVEO for the treatment of adults with complicated intra-abdominal infections

EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA


India reaffirms commitment to global pharmaceutical standardization and regulatory convergence: Anupriya Patel
Policy | February 06, 2025

India reaffirms commitment to global pharmaceutical standardization and regulatory convergence: Anupriya Patel

International Meeting of World Pharmacopoeias serves as a vital platform to foster international collaboration in pharmacopoeial science and regulatory harmonization


Alkem launches Kojiglo serum to manage facial hyperpigmentation
News | February 05, 2025

Alkem launches Kojiglo serum to manage facial hyperpigmentation

This innovative formulation combines cutting-edge ingredients is a first of its kind in India to have a Duo-Lipo technology


FDA approves Roche’s Susvimo as the first and only continuous delivery treatment diabetes-related blindness
Drug Approval | February 05, 2025

FDA approves Roche’s Susvimo as the first and only continuous delivery treatment diabetes-related blindness

Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)


Somaiya Vidyavihar University to host conference on ‘Clinical Translation of Biomaterials for Future Healthcare’
News | February 04, 2025

Somaiya Vidyavihar University to host conference on ‘Clinical Translation of Biomaterials for Future Healthcare’

It will bring together renowned global experts in the field to discuss groundbreaking advances in biomaterials and their clinical applications


Gland Pharma reports Q3 FY25 revenue at Rs. 1,384 Cr
News | February 04, 2025

Gland Pharma reports Q3 FY25 revenue at Rs. 1,384 Cr

Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin


CuraTeQ Biologics receives positive opinion for biosimilar Dyrupeg from EMA
News | February 03, 2025

CuraTeQ Biologics receives positive opinion for biosimilar Dyrupeg from EMA

Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia


Jubilant Pharmova Q3 FY25 revenue up 9%
News | February 03, 2025

Jubilant Pharmova Q3 FY25 revenue up 9%

EBITDA grew by 11% on a YoY basis to Rs. 296 crore due to improved performance in CDMO Sterile Injectables, CRDMO and Generics


Allergan Aesthetics launches new AA signature program at IMCAS 2025 to redefine patient-centric, multimodal treatment plans
News | February 01, 2025

Allergan Aesthetics launches new AA signature program at IMCAS 2025 to redefine patient-centric, multimodal treatment plans

AA Signature provides an innovative approach to treatment planning that focuses on patient outcomes